Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Vilin Bio Med's Enterprise Value is ₹669.0 Mil.
Vilin Bio Med's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-13.6 Mil. Therefore, Vilin Bio Med's EV-to-FCF for today is -49.30.
The historical rank and industry rank for Vilin Bio Med's EV-to-FCF or its related term are showing as below:
NSE:VILINBIO'
s EV-to-FCF Range Over the Past 10 Years
Min: -49.3 Med: -20.4 Max: 170.21
Current: -49.3
During the past 7 years, the highest EV-to-FCF of Vilin Bio Med was 170.21. The lowest was -49.30. And the median was -20.40.
NSE:VILINBIO's EV-to-FCF is ranked worse than 100% of 564
companies
in the Drug Manufacturers industry
Industry Median: 20.01
vs NSE:VILINBIO: -49.30
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vilin Bio Med (NSE:VILINBIO) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vilin Bio Med's PE Ratio (TTM) for today is calculated as:
Vilin Bio Med's share price for today is ₹44.70.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vilin Bio Med's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹1.260.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vilin Bio Med EV-to-FCF Related Terms
Vilin Bio Med EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Vilin Bio Med's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vilin Bio Med's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vilin Bio Med EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vilin Bio Med's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Vilin Bio Med's EV-to-FCF falls into.
Vilin Bio Med's current Enterprise Value is ₹669.0 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Vilin Bio Med's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-13.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vilin Bio Med (NSE:VILINBIO) has a EV-to-FCF of -49.30 as of Aug. 30, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vilin Bio Med and its competitors. According to the industry distribution chart, Vilin Bio Med ranks #999999 out of 564 companies in the Drug Manufacturers industry.
Is Vilin Bio Med's EV-to-FCF too high?
Vilin Bio Med's current EV-to-FCF is -49.30. Based on the distribution chart, Vilin Bio Med ranks #999999 out of 564 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vilin Bio Med has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vilin Bio Med's EV-to-FCF compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vilin Bio Med ranks #999999 out of 564 companies for EV-to-FCF. This places Vilin Bio Med in the lower half of its industry. The industry median EV-to-FCF is 20.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.01, based on 564 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Vilin Bio Med and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vilin Bio Med's current EV-to-FCF is -49.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vilin Bio Med stock overvalued right now?
Based on GuruFocus' analysis, Vilin Bio Med (NSE:VILINBIO) is currently considered Possible Value Trap. The stock's GF Value™ is ₹75.10, compared to a current price of ₹44.70 — trading 40.5% below its estimated fair value. The current EV-to-FCF is -49.30. Vilin Bio Med's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Vilin Bio Med (NSE:VILINBIO), the current EV-to-FCF is -49.30 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vilin Bio Med (NSE:VILINBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Vilin Bio Med stock appears to be undervalued.
The current stock price of ₹44.70 is trading 40.5% below its estimated GF Value™ of ₹75.10.
GuruFocus considers Vilin Bio Med to be Possible Value Trap.
Key valuation signals for NSE:VILINBIO:
EV-to-FCF: -49.30
GF Value™: ₹75.10 vs. price of ₹44.70 (40.5% below fair value)
No single metric tells the full story. See the NSE:VILINBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vilin Bio Med Ltd is engaged in the domestic business of manufacturing Pharmaceuticals products. It is manufacturing pharmaceutical formulations such as Oral Liquids, Dry syrups, Sachets, External Preparations, Beta and Non-Beta Lactam tablets, and Capsules and Nutritional Food supplements.
69GF Score
Get the complete analysis for NSE:VILINBIO
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:VILINBIO has been successfully added to your 
